Skip to main content
Premium Trial:

Request an Annual Quote

Mya Thomae, Harjit Kullar

Transgenomic has elected Mya Thomae to its board of directors. She is currently vice president of regulatory affairs at Illumina. Before that, she served as CEO of Myraqa, a diagnostics regulatory consulting firm, which was acquired by Illumina in 2014.

Transgenomic has also appointed Harjit Kullar vice president of marketing for biomarker discovery and genetic assays and platforms. He previously was content marketing leader for cross-functional global digital and web-based initiatives at Bio-Rad. Before that, he was director of product marketing, genomics, at Thermo Fisher Scientific.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.